30 Jan 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Zenotec Biotechnology, a bioscience start-up founded in October 2012, will invest $993,267 (RM3.06 million) to develop its collagen wound healing management product. The product is specially designed for glaucoma and diabetes patients.
News reports emerging from Malaysia stated that the tissue re-engineering and wound healing technology of Zenotec Biotechnology is believed to be the first-of-its-kind in the region.
Zenotec Biotechnology is one of the incubatees at Technology Park Malaysia's Biotech Incubation Center in Kuala Lumpur. The technology of the company was acquired from a renowned Taiwanese inventor and will be enhancement further through R&D for the intellectual property to be patented in Malaysia.
The investment will be made to set up a pilot plant and further R&D on the acquired technology.